RC-198

N/A

Report date: 2024/04/22 11:16:26

Base Information

Drug NameRC-198
Drug Alias NameRC-198
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-15 modulatorsInterleukin-15 receptor subunit alpha modulators
TargetsInterleukin-15Interleukin-15 receptor subunit alpha
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesRemeGen Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesRemeGen Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A